# Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer

> **NCT03109249** · PHASE1 · COMPLETED · sponsor: **Sun Pharma Advanced Research Company Limited** · enrollment: 142 (actual)

## Conditions studied

- Recurrent or Metastatic Breast Cancer

## Interventions

- **DRUG:** SPARC1613
- **DRUG:** Reference1613

## Key facts

- **NCT ID:** NCT03109249
- **Lead sponsor:** Sun Pharma Advanced Research Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-14
- **Primary completion:** 2018-10-04
- **Final completion:** 2018-10-04
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2019-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03109249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03109249, "Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT03109249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*